Master Docket No. 3:25md3140

On February 7, 2025, the Judicial Panel on Multidistrict Litigation centralized and transferred the Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, to this Court for pretrial proceedings before Judge M. Casey Rodgers.  The transferred actions share allegations that injectable contraceptive Depo-Provera, or its generic equivalents, can cause users to develop one or more meningiomas, a type of brain tumor.  Defendants maintain that the medication is safe and effective.  The Panel determined that these actions involve common questions of fact, such as “whether Depo-Provera causes meningioma, whether defendants knew of the alleged risk of meningioma, whether they failed to adequately warn of this risk, and whether defendants failed to promote safer alternatives, such as Depo-SubQ Provera 104, which plaintiffs contend is safer due to its lower dose of medroxyprogesterone acetate and its administration through subcutaneous injection (rather than the intramuscular injection used for Depo-Provera).”  The Panel also found that centralization would “eliminate duplicative discovery; prevent inconsistent pretrial rulings; and conserve the resources of the parties, their counsel, and the judiciary.”

This website is provided for the convenience of all interested parties.  For a complete record of the filings in this matter to date, please log into PACER and review the master MDL docket, Case No. 3:25md3140.